|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization.
|
17374397 |
2007 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The analyses of publically available human breast tumor microarray gene expression database show that low embigin levels correlate with short survival of breast tumor patients, particularly with basal-like tumor patients, and embigin expression is low specifically in patients with basal-like, ER-/HER2- tumors.
|
26090721 |
2015 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Vaccinations using DC-AxCAgp70/GM-CSF/IL-12 or DC-AxCAgp70/IL-12 could elicit potent therapeutic immunity in s.c. tumor models; tumor-free mice were observed in these vaccination groups.
|
16525645 |
2006 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We show here for the first time that (a) antigen-specific immune responses induced by vaccines were optimally augmented when anti-CD25 mAb was given at the same time as vaccination; (b) anti-CD25 mAb administration in combination with vaccines equally augmented T-cell immune responses specific for a self-antigen as well as those specific for a non-self antigen; (c) whereas the combined use of vaccines and anti-CD25 mAb enhanced antigen-specific immune responses, it was not sufficient to eliminate established tumors; (d) the addition of external beam radiation of tumors to the vaccine/anti-CD25 mAb regimen was required for the elimination of established tumors; and (e) T cells from mice receiving the combination therapy showed significantly higher T-cell responses specific not only for the antigen in the vaccine but also for additional tumor-derived antigens (p53 and gp70).
|
15958639 |
2005 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In CEA(+) tumor-bearing mice vaccinated with the CEA/TRICOM s.c./i.t. regimen, T-cell responses could be detected not only to CEA encoded in vaccine vectors but also to other antigens expressed on the tumor itself: wild-type p53 and an endogenous retroviral epitope of gp70.
|
15788693 |
2005 |
|
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
We further investigated the sequence variability of the HCV genomic region that entirely encodes the envelope proteins (gp35 and gp70); these sequences were derived from virus isolated during the acute and chronic phases of hepatitis in one patient, and we found that HVR1 was a major site for genetic mutations in HCV after the onset of hepatitis.
|
7518526 |
1994 |
|
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
To evaluate the implications of sequence variability in HVRI of HCV, we investigated the sequence variability of the whole envelope-protein(gp35 and gp70)-coding regions of HCV genome derived from patient M in acute and relapsed phases (8-month interval) of hepatitis.
|
7515022 |
1994 |
|
Hepatitis C
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Hepatitis C virus (HCV) genome shows extensive sequence diversity at 2 hypervariable regions (HVR1 and HVR2) of the putative envelope glycoprotein (gp70).
|
8314302 |
1994 |
|
Hepatitis C
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We confirmed that two hypervariable regions (HVR1 and HVR2) were present in this amplified region, as described in our previous report (Hijikata et al., 1991a) and we found that the HVR1 regions of HCV-J and HCV-US were 27 and 21 amino acids in length, respectively, and began from the N-terminal amino acid of gp70.
|
1314471 |
1992 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to characterize lymphomas arising in cats in Brazil anatomically and microscopically, and to correlate these data with FeLV infection as determined by immunohistochemistry for the FeLV gp70 antigen.
|
30691602 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.030 |
Biomarker
|
disease |
BEFREE |
F1 crosses of lupus-prone New Zealand Black (NZB) and 129 mice to Snerv1/Snerv2<sup>-/-</sup> mice failed to restore NEERV repression, demonstrating that loss of SNERV underlies the lupus autoantigen gp70 overproduction that promotes nephritis in susceptible mice and that SNERV encodes for Sgp3 (in NZB mice) and Gv-1 loci (in 129 mice).
|
30709743 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Because of the localization of the macroH2A1 gene encoding macroH2A histone variants within the Sgp3 interval and of an up-regulated transcription of endogenous retroviral sequences in macroH2A1-deficient C57BL/6 (B6) mice, we investigated whether macroH2A1 is a candidate gene for Sgp3. macroH2A1-deficient B6 mice carrying the 129-derived Sgp3 locus, which was co-transferred with the 129 macroH2A1 mutant gene, displayed increased levels of serum gp70 and hepatic retroviral gp70 RNAs comparable to those of B6.NZB-Sgp3 congenic mice bearing the Sgp3 locus of lupus-prone NZB mice.
|
20833509 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Given critical roles of TLR7 and TLR9 in the pathogenesis of SLE, we assessed their contribution to the acute phase expression of serum gp70, and defined a pivotal role of the Sgp3 (serum gp70 production 3) and Sgp4 loci in this response.
|
20619604 |
2010 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Immune responses were not detected either to Rev M10 or to Moloney murine leukemia virus gp70 envelope protein.
|
9448309 |
1998 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The determinant was present on the cell surface and was distinct from murine leukemia virus gp70 by absorption studies.
|
3531330 |
1986 |
|
Lupus Vulgaris
|
0.020 |
Biomarker
|
disease |
BEFREE |
F1 crosses of lupus-prone New Zealand Black (NZB) and 129 mice to Snerv1/Snerv2<sup>-/-</sup> mice failed to restore NEERV repression, demonstrating that loss of SNERV underlies the lupus autoantigen gp70 overproduction that promotes nephritis in susceptible mice and that SNERV encodes for Sgp3 (in NZB mice) and Gv-1 loci (in 129 mice).
|
30709743 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.020 |
Biomarker
|
disease |
BEFREE |
F1 crosses of lupus-prone New Zealand Black (NZB) and 129 mice to Snerv1/Snerv2<sup>-/-</sup> mice failed to restore NEERV repression, demonstrating that loss of SNERV underlies the lupus autoantigen gp70 overproduction that promotes nephritis in susceptible mice and that SNERV encodes for Sgp3 (in NZB mice) and Gv-1 loci (in 129 mice).
|
30709743 |
2019 |
|
Lupus Erythematosus
|
0.020 |
Biomarker
|
disease |
BEFREE |
F1 crosses of lupus-prone New Zealand Black (NZB) and 129 mice to Snerv1/Snerv2<sup>-/-</sup> mice failed to restore NEERV repression, demonstrating that loss of SNERV underlies the lupus autoantigen gp70 overproduction that promotes nephritis in susceptible mice and that SNERV encodes for Sgp3 (in NZB mice) and Gv-1 loci (in 129 mice).
|
30709743 |
2019 |
|
Tuberculosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mycobacterium tuberculosis isolates (n=355) were tested against three first-line antimycobacterial agents (ethambutol [EMB], isoniazid [INH], rifampin [RIF]) using the MYCOTB plate and either the MGIT 960 (site 1, n=142) or VersaTREK (site 2, n=213) systems.
|
29422273 |
2018 |
|
Tuberculosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Proper management of multidrug-resistant tuberculosis (MDR-TB) requires accurate drug susceptibility testing (DST) of Mycobacterium tuberculosis isolates to other (ethambutol [EMB], pyrazinamide, and streptomycin [SM]) first-line drugs.
|
29336677 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.020 |
Biomarker
|
disease |
BEFREE |
However, all 18 EMB-resistant MDR-TB strains and 33 of 42 EMB-susceptible MDR-TB strains contained an embB mutation (κ = 0.14, poor agreement).
|
29336677 |
2018 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We proposed that embigin and p21<sup>WAF1</sup> could be used as prognostic biomarkers and a strategy to inhibit S100A4-embigin binding could be a therapeutic approach for prostate cancer patients.
|
30041429 |
2018 |
|
Lupus Vulgaris
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Because of the localization of the macroH2A1 gene encoding macroH2A histone variants within the Sgp3 interval and of an up-regulated transcription of endogenous retroviral sequences in macroH2A1-deficient C57BL/6 (B6) mice, we investigated whether macroH2A1 is a candidate gene for Sgp3. macroH2A1-deficient B6 mice carrying the 129-derived Sgp3 locus, which was co-transferred with the 129 macroH2A1 mutant gene, displayed increased levels of serum gp70 and hepatic retroviral gp70 RNAs comparable to those of B6.NZB-Sgp3 congenic mice bearing the Sgp3 locus of lupus-prone NZB mice.
|
20833509 |
2010 |
|
Lupus Erythematosus, Discoid
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Because of the localization of the macroH2A1 gene encoding macroH2A histone variants within the Sgp3 interval and of an up-regulated transcription of endogenous retroviral sequences in macroH2A1-deficient C57BL/6 (B6) mice, we investigated whether macroH2A1 is a candidate gene for Sgp3. macroH2A1-deficient B6 mice carrying the 129-derived Sgp3 locus, which was co-transferred with the 129 macroH2A1 mutant gene, displayed increased levels of serum gp70 and hepatic retroviral gp70 RNAs comparable to those of B6.NZB-Sgp3 congenic mice bearing the Sgp3 locus of lupus-prone NZB mice.
|
20833509 |
2010 |